Related Experiment Video
Updated: Apr 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies
Abhishek Jaiswal1, Seth Goldbarg1
1Division of Cardiology, New York Hospital Queens/Weill Medical College of Cornell University, Flushing, NY 11355, USA.
Abstract:
Dofetilide is an effective antiarrhythmic agent for conversion of atrial fibrillation and atrial flutter as well as maintenance of sinus rhythm in appropriately selected patients. However, as with other antiarrhythmic agents, proarrhythmia is a known adverse effect. The risk of dofetilide induced torsade de pointes (Tdp) is low when used with strict dosing criteria guided by renal function, QT interval and concomitant drug therapy. Benefit from dofetilide use must be individualized and weighed against the side effects and the role of other available treatment options. In this review, we discuss the underlying mechanism, risk factors and precautionary measures to avoid dofetilide induced QT prolongation and ventricular tachycardia/Tdp. We suggest a scheme for the management of QT prolongation, ventricular arrhythmia and Tdp as well.
Insights
Dofetilide effectively treats atrial fibrillation but carries a risk of proarrhythmia. Strict adherence to dosing guidelines minimizes the risk of torsades de pointes (Tdp) when using this antiarrhythmic drug.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dofetilide is an effective antiarrhythmic medication for atrial fibrillation and flutter.
- Proarrhythmia, including torsades de pointes (Tdp), is a known adverse effect of dofetilide.
- Risk of Tdp is minimized with strict dosing based on renal function, QT interval, and drug interactions.
Purpose of the Study:
- To review the mechanism, risk factors, and prevention of dofetilide-induced QT prolongation and Tdp.
- To outline a management strategy for QT prolongation, ventricular arrhythmia, and Tdp.
Main Methods:
- Literature review of dofetilide's antiarrhythmic properties and adverse effects.
- Analysis of risk factors contributing to QT prolongation and Tdp.
- Development of a clinical management scheme.
Main Results:
- Dofetilide efficacy in rhythm conversion and maintenance is established.
- Proarrhythmia risk is significantly reduced by individualized dosing and monitoring.
- Clear guidelines for managing adverse events are crucial.
Conclusions:
- Dofetilide offers significant benefits for selected patients with atrial arrhythmias.
- Careful patient selection and adherence to dosing protocols are paramount to safety.
- A structured approach to managing QT prolongation and Tdp enhances patient outcomes.
More Related Videos
10:41Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias II: Classification of Tachyarrhythmias